DAY ONE — Psychofuture · Live Watchlist

‹

DAY ONE · Psychofuture · Live Watchlist

Psychofuture

Forward IPO Intelligence · Reasoning per Company

Forward intelligence on every name on the watchlist. Each report is fully scored before pricing day, with the math, the sentiment read, and the founder profile published in writing. Click any card to read the full per-axis reasoning behind the score — including, where relevant, the contrarian dissent that overrides consensus.

★ Highest Conviction · Rank 1 of 21

Stripe

Fintech infrastructure

Forward · est. 2026/2027 · $70B private

80.5

Composite Pop Score

Strong Buy

The only forward in the entire watchlist landing in the Strong predicted bucket (≥80, predicted +30%+). Profitable, deeply embedded, beloved Collison brothers. If this prices in 2026/2027, the model says it pops big.

PBI 6/30 · Low bucket · 88% historical hit rate

Forward · H2 2026 / 2027 · $134B private

79.9

Composite Pop Score

Strong Buy

"Snowflake of AI" thesis with $5.4B+ ARR. Goldman + JPM engaged. Risk: peak expectations could compress the actual pop relative to Snowflake's +112% precedent.

PBI 9/30 · Low bucket

Forward · est. 2026 · $14.6B Series C

72.4

Composite Pop Score

Strong Buy

European AI champion with $14B Microsoft GPU deal + OpenAI Stargate Norway. Pre-scale revenue but locked-in demand. Founder Josh Payne's underdog story is a real PR asset.

PBI 10/30 · Low bucket

Forward · Q2 2026 · refiled Apr 2026

70.0

Composite Pop Score

Strong Buy

Wafer-scale Nvidia challenger with $10B OpenAI compute deal. CFIUS finally cleared after G42 restructure. Customer concentration is the live risk.

PBI 9/30 · Low bucket

Read full reasoning

⚠ Contrarian Call · Rank 5 of 21

SpaceX

Space

Forward · est. 2026 · ~$350B private

73.0

Composite Pop Score

Buy · Demoted

Market consensus says "no-brainer Strong Buy" — composite math agrees at 67.5. But Musk's PBI of 22/30 triggers the verdict guardrail. Demoted to Buy. Read why we're going against consensus.

PBI 22/30 · High bucket · 40% historical hit rate

Forward · rumored 2026 · $1.4B private

66.7

Composite Pop Score

Strong Buy

Profitable consumer beverage at scale (rare). Cult brand with viral marketing playbook recognized as best-in-class. Cuts through the cooler consumer-IPO window.

PBI 7/30 · Low bucket · cleanest of the consumer forwards

Read full reasoning

Rank 7 of 21

Discord

Consumer / gaming social

Forward · rumored 2026 · ~150M MAU

62.5

Composite Pop Score

Strong Buy

Cult Gen Z brand with strong gaming/community moats. Monetization still maturing. Reddit's +48% Day-1 in March 2024 is the most relevant comparable.

PBI 9/30 · Low bucket

Read full reasoning

Rank 8 of 21

Blackstone Digital Infrastructure Trust

AI-era data center REIT

Forward · prices week of 2026-05-11 · NYSE: BXDC · $1.75B at $20/share

77.6

Composite Pop Score

Strong Buy

Highest score in the May 11 cohort. Externally-managed AI-data-center REIT with priority sourcing rights from Blackstone. Peak market-cycle alignment (m=85), institutional cash-flow profile, full bulge-bracket syndicate. Watch for BREIT-redemption-memory drag at retail level.

PBI 8/30 · Low bucket · institutional governance

Read full reasoning

Rank 9 of 21

Fervo Energy

Advanced geothermal · climate-tech

Forward · prices week of 2026-05-11 · Nasdaq: FRVO · $1.33B at $6.5B valuation

73.7

Composite Pop Score

Strong Buy

Largest climate-tech IPO of 2026 with the strongest narrative profile in the cohort (PH=80). First commercial EGS plant in the US, Google 115MW offtake, technical-founder profile (Tim Latimer, ex-BHP drilling engineer + Stanford). The AI-data-center-power bridge story has unusual cross-narrative reach.

PBI 8/30 · Low bucket

Read full reasoning

Rank 10 of 21

HawkEye 360

Defense / SIGINT — RF satellite intelligence

Forward · prices week of 2026-05-11 · NYSE: HAWK · $400M at $2.4–$2.7B cap

69.2

Composite Pop Score

Strong Buy

Profitable defense-data IPO ($117.6M revenue, $2.6M net income FY 2025) riding the post-Swarmer momentum. Military-disciplined CEO (John Serafini, Airborne Ranger, HBS, Harvard Kennedy). 61% US-Gov customer concentration is the swing variable; AI-enabled signal-analytics narrative is the upside.

PBI 7/30 · Low bucket · military-disciplined CEO

Read full reasoning

Rank 11 of 21

IMPACT Therapeutics

Synthetic-lethality precision oncology · Asia

Forward · prices 2026-05-11 · trades 2026-05-13 · HKEX 18A · ~$117M · cornerstone Tencent

66.4

Composite Pop Score

Strong Buy

First Asia-anchored watchlist entry post-HSBC pivot. NMPA-approved Senaparib (1L ovarian-cancer maintenance) + Phase III published in Nature Medicine + Tencent cornerstone. Technical-founder profile (Dr. Sui Xiong Cai, PhD U. of Oregon, 90+ patents). First packet built under updated zh-Hans/zh-Hant source-language schema.

PBI 8/30 · Low bucket · Asia anchor

Read full reasoning

Rank 12 of 21

Suja Life

Functional beverages · consumer staples

Forward · prices ~2026-05-07 · Nasdaq: SUJA · $200M (up to $213M)

61.3

Composite Pop Score

Strong Buy

$326.6M revenue, +26% YoY across Suja Organic, Vive Organic, Slice Soda. Maria Stipp CEO (ex-Sapporo-Stone Brewing, Lagunitas). Up-C structure with Paine Schwartz retaining control is the bigger drag than the consumer-staples sector. Mild-bucket call — directionally positive but not a +30%+ Day-1 pop.

PBI 7/30 · Low bucket

Read full reasoning

Rank 13 of 21

Mobia Medical

Implantable nerve stimulation · medical devices

Forward · prices week of 2026-05-04 to 2026-05-11 · Nasdaq: MOBI · $150–$160M

58.1

Composite Pop Score

Buy

Formerly MicroTransponder (renamed February 2026). FDA-approved Vivistim Vagus Nerve Stim for chronic stroke rehab; $32M FY 2025 revenue. Will Rosellini founder profile is unusually credentialed (7 grad degrees) — mild α-axis flag but no specific governance concern. Single-product, 19-year operational history, slow path to scale.

PBI 8/30 · Low bucket

Read full reasoning

Rank 14 of 21

Odyssey Therapeutics

Autoimmune / inflammatory biotech

Forward · prices week of 2026-05-11 · Nasdaq: ODTX · $225M at $845M cap

56.1

Composite Pop Score

Buy

Clinical-stage autoimmune biotech, $700M+ raised since 2021 from OrbiMed and SR One. Repeat-founder Gary Glick (prev. Lycera and IFM Therapeutics). The 2024 withdrawn-IPO complication is a meaningful Psychohistory drag — the 'second attempt' framing dampens Day-1 enthusiasm. Mild-bucket call.

PBI 7/30 · Low bucket

Read full reasoning

⚠ Avoid Calls · Where We're Saying No

Forward intelligence reports where the model says don't buy at IPO. These are the credibility trades — anyone can call a hot AI IPO; the harder calls are the unfashionable ones. If these prove out, the public ledger has its strongest possible evidence.

⚠ Avoid · Rank 15 of 21

Shein

Fast fashion · Chinese-tied

Forward · H2 2026 · $30-50B HK or London

43.0

Composite Pop Score

Avoid

Active Texas AG investigation. Amnesty calls a London listing "a badge of shame." Founder reclusive, governance opaque, refused parliamentary questions on Xinjiang cotton. Multi-axis weakness.

PBI 15/30 · Mid bucket · ESG screens block institutional flow

Read full reasoning

⚠ Strong Avoid · Rank 16 of 21

Bolt Financial

Fintech / one-click checkout

Forward · 2026/27 · raising $600M after 97% peak crash

37.3

Composite Pop Score

Strong Avoid

Highest founder-risk reading on the entire watchlist. Breslow PBI 21/30 — public meltdowns, Y Combinator/Stripe Twitter feuds, sued his own investors, returned as CEO after being pushed out. The PBI guardrail thesis in a single picture.

PBI 21/30 · High bucket · founder-risk extreme

Read full reasoning

⚠ Avoid · Rank 17 of 21

Gopuff

Instant delivery

Forward · 2026 · ~96% near-term IPO probability

49.0

Composite Pop Score

Avoid

Down round from $15B to $8.5B. Three layoff rounds. Becoming-but-not-yet-profitable. Founders are clean operators (PBI 9 — Low bucket) — this is a fundamentals call, not a behavioral one.

PBI 9/30 · Low bucket · weak Psychofinance is what kills it

Read full reasoning

⚠ Avoid · Rank 18 of 21

Yuga Labs

NFT / web3 (BAYC creator)

Forward · speculative 2026/27 · post-NFT-crash

43.0

Composite Pop Score

Avoid

NFT category collapse 90%+ from peak. BAYC brand recognizable but not aspirational. Multi-year IP litigation, settled April 2026. Still cash-rich from $450M raise but no clear post-NFT business model.

PBI 12/30 · Mid bucket · category dead, brand fading

Read full reasoning

⚠ Strong Avoid · Rank 19 of 21

Flow / Adam Neumann

Residential real estate · a16z-backed

Forward · speculative 2027+ · $350M from a16z

35.0

Composite Pop Score

Strong Avoid

The canonical test of the PBI guardrail thesis. Neumann is the founder whose previous company (WeWork) bankrupted in 2023. PBI 25/30 — among the highest reading possible. If the model is right about anything, it's right about this.

PBI 25/30 · High bucket · Neumann effect

Read full reasoning

⚠ Edge Case · Avoid · Rank 20 of 21

Carta

Cap-table SaaS · enterprise fintech

Forward · 2026/27 · ~$2B secondary (down 73% from $7.4B)

42.0

Composite Pop Score

Avoid

The edge-case demonstration. Cap-table business itself is profitable enterprise SaaS — shallow research lands at Buy. Deep research moves it to Avoid: Linear scandal, 1,550% negative-press spike, "volatile leader" pattern, COO departure, multiple harassment lawsuits. Lock-grade PB and PH packets in data/packets/carta/.

PBI 20/30 · High bucket · why source rigor matters

Read full reasoning

⚠ Avoid · Rank 21 of 21

Optimi Health

Psychedelic medicine · pharmaceutical mfg

Forward · prices week of 2026-05-08 · Nasdaq: OPTI · $17.5M uplisting from CSE

43.4

Composite Pop Score

Avoid

Health-Canada-licensed psychedelic-pharmaceuticals manufacturer. Sub-$25M Nasdaq uplisting from CSE — structural buyer pool is narrow. Only Avoid in the May 11 cohort. Three drags: psychedelic-stock sector fatigue post-2021 hype, sub-$25M uplisting structure, interim CEO unfilled since October 2024. PBI 10/30 — Mid bucket, the only Mid-bucket on the watchlist.

PBI 10/30 · Mid bucket · interim-CEO drag

Read full reasoning

Under Review · 2026-05-09 batch · v1.2 methodology

10 candidates added 2026-05-09

Generated from data/registry.json via scripts/build.py. 6 confirmed-filing review entries scored under Psymetry v1.2 (Strong Buy ≥75, Hold tier added). 3 speculative-pipeline entries marked Score Pending (no S-1 filed). 1 post-hoc reference (priced before our scoring date — NOT in forensic chain). Investor-network ripple markers shown where data was available. Full digest → · MR-002 →

Review · v1.2 · 2026-05-09

Chaozhou Three-Circle (Group) Co., Ltd.

Advanced electronic ceramic materials and components

June 2026 (CSRC-approved; draft prospectus December 2025)

61.8

v1.2 composite · Buy

Buy

Status: review under Psymetry v1.2. Source

PBI 8/30 · Low bucket

Packet building — review pending

Review · v1.2 · 2026-05-09

Wanbang Digital Energy Co., Ltd.